Trials / Unknown
UnknownNCT04628806
Heat Shock Protein (HSP) 70 to Quantify and Characterize Circulating Tumor Cells
Heat Shock Protein (HSP) 70 to Quantify and Characterize Circulating Tumor Cells in Patients With Advanced or Metastatic Tumors.
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 120 (estimated)
- Sponsor
- Charite University, Berlin, Germany · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study investigates the ability of heat shock protein HSP70 to isolate and quantify circulating tumor cells (CTCs) in patients with advanced or metastatic tumors. CTCs will be isolated from peripheral blood before antineoplastic treatment and again after three months. Isolation using HSP70 will be compared with standard CTC isolation by EpCAM. Additionally, imaging parameters of the primary tumor (if available) and metastases will be analysed and correlations between molecular alterations and imaging parameters will be assesed.
Conditions
- Melanoma Stage IV
- Sarcoma
- Squamous Cell Carcinoma
- Pancreatic Cancer Stage IV
- Prostate Cancer
- Breast Cancer Stage IV
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | CTC isolation by HSP70 | patients will receive additional blood examinations with quantification of circulating tumor cells by HSP70 antibodies and EpCAM. |
Timeline
- Start date
- 2021-02-17
- Primary completion
- 2022-02-01
- Completion
- 2022-05-01
- First posted
- 2020-11-16
- Last updated
- 2021-05-14
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT04628806. Inclusion in this directory is not an endorsement.